X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-09-30 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Chief Scientific Officer | S - Sale | $23.04 | -536 | 54,305 | -1% | -$12,349 | ||||||
2026-10-01 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $147.90 | -15,000 | 566,683 | -3% | -$2,218,508 | ||||||
2026-10-01 | HALO | Halozyme Therapeutics, Inc. | Posard Matthew L. | Dir | S - Sale | $108.54 | -5,230 | 53,609 | -9% | -$567,661 | ||||||
| M | 2026-10-01 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $97.09 | -34,000 | 39,398,320 | 0% | -$3,301,069 | |||||
2026-10-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $27.02 | -34,501 | 234,367 | -13% | -$932,260 | ||||||
| D | 2026-10-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $26.93 | -16,141 | 0 | -100% | -$434,743 | |||||
| D | 2026-10-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | EVP, Chief Scientific Ofc, COO | S - Sale+OE | $56.67 | -2,250 | 145,435 | -2% | -$127,513 | |||||
2026-10-01 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.69 | +19,050 | 3,322,954 | +1% | +$165,634 | ||||||
2026-10-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $24.41 | -187 | 50,984 | 0% | -$4,565 | ||||||
2026-10-01 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $0.92 | +20,000 | 420,000 | +5% | +$18,400 | ||||||
| D | 2026-09-29 | RVMD | Revolution Medicines, Inc. | Sandler Alan B. | Chief Development Officer | S - Sale+OE | $202.14 | -6,309 | 52,559 | -11% | -$1,275,294 | |||||
| D | 2026-10-01 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $113.80 | -30,000 | 666,568 | -4% | -$3,413,917 | |||||
2026-09-29 | SLBT | Sl Science Holding Ltd | Wang Ching-Dong | CEO, 10% | P - Purchase | $2,272,650.00 | +4,545,306 | 333,832,129 | +1% | +$2,147,483,647 | ||||||
| D | 2026-09-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $27.06 | -7,500 | 32,316 | -19% | -$202,921 | |||||
2026-09-29 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.03 | +1,000 | 384,885 | 0% | +$1,030 | ||||||
| M | 2026-09-28 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $88.59 | +715,592 | 20,191,214 | +4% | +$63,397,609 | |||||
2026-09-28 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $83.58 | +418,323 | 19,515,907 | +2% | +$34,963,077 | ||||||
| M | 2026-09-29 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $98.19 | -66,000 | 39,432,320 | 0% | -$6,480,659 | |||||
2026-09-28 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $72.57 | +807,840 | 19,121,134 | +4% | +$58,625,708 | ||||||
2026-09-28 | DTIL | Precision Biosciences Inc | Frankel Stanley | Dir | P - Purchase | $6.00 | +1,000 | 41,478 | +2% | +$6,000 | ||||||
2026-09-25 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | SVP, GC | S - Sale | $207.32 | -765 | 51,776 | -1% | -$158,600 | ||||||
2026-09-25 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $6.27 | +1,135 | 45,481 | +3% | +$7,116 | ||||||
2026-09-25 | DTIL | Precision Biosciences Inc | Germano Geno J | Dir | P - Purchase | $6.28 | +2,609 | 47,492 | +6% | +$16,385 | ||||||
| M | 2026-09-24 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.53 | +31,763 | 3,303,904 | +1% | +$270,800 | |||||
| DM | 2026-09-24 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $200.46 | -3,708 | 39,765 | -9% | -$743,285 | |||||
| M | 2026-09-25 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $99.88 | +10,000 | 960,413 | +1% | +$998,784 | |||||
| M | 2026-09-25 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $98.57 | -61,000 | 39,498,320 | 0% | -$6,012,500 | |||||
| D | 2026-09-24 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale+OE | $190.00 | -12,946 | 48,369 | -21% | -$2,459,740 | |||||
2026-09-23 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $36.36 | -2,846 | 176,545 | -2% | -$103,481 | ||||||
| D | 2026-09-24 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $177.38 | -5,203 | 613,699 | -1% | -$922,907 | |||||
2026-09-24 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $1.14 | +2,500 | 400,000 | +1% | +$2,850 | ||||||
| D | 2026-09-22 | RVMD | Revolution Medicines, Inc. | Anderson Elizabeth M | Dir | S - Sale+OE | $193.04 | -10,143 | 46,323 | -18% | -$1,958,016 | |||||
| D | 2026-09-22 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $60.24 | -10,400 | 94,784 | -10% | -$626,460 | |||||
2026-09-22 | ENGN | Engene Therapeutics Inc. | Grossman William | Interim Chief Medical Officer | P - Purchase | $1.97 | +5,102 | 5,102 | New | +$10,051 | ||||||
| M | 2026-09-23 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $99.17 | -69,000 | 39,559,320 | 0% | -$6,842,742 | |||||
2026-09-23 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.05 | +1,900 | 383,885 | 0% | +$1,995 | ||||||
| D | 2026-09-21 | ETRA | Electra Therapeutics, Inc. | Gordon Carl L | Dir, 10% | P - Purchase | $15.00 | +1,333,333 | 1,758,279 | +314% | +$19,999,995 | |||||
| D | 2026-09-21 | ETRA | Electra Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $15.00 | +1,333,333 | 1,758,279 | +314% | +$19,999,995 | |||||
2026-09-23 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $100.00 | +5,000 | 1,074,046 | 0% | +$500,000 | ||||||
2026-09-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $165.49 | -348 | 73,303 | 0% | -$57,591 | ||||||
2026-09-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $165.49 | -294 | 116,720 | 0% | -$48,654 | ||||||
| D | 2026-09-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $165.49 | -1,687 | 618,902 | 0% | -$279,183 | |||||
| D | 2026-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $13.65 | -1,635 | 8,617 | -16% | -$22,318 | |||||
2026-09-18 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale | $196.94 | -1,764 | 40,352 | -4% | -$347,402 | ||||||
| M | 2026-09-21 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $99.50 | -79,000 | 39,628,320 | 0% | -$7,860,757 | |||||
| D | 2026-09-21 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale+OE | $180.00 | -5,426 | 48,369 | -10% | -$976,680 | |||||
| D | 2026-09-17 | CRSP | Crispr Therapeutics AG | Behbahani Ali | Dir | S - Sale+OE | $57.09 | -13,679 | 16,666 | -45% | -$780,935 | |||||
| D | 2026-09-17 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $157.99 | -356,546 | 620,589 | -36% | -$56,330,724 | |||||
| D | 2026-09-16 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $28.06 | -115,406 | 223,367 | -34% | -$3,238,004 | |||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Sandler Alan B. | Chief Development Officer | S - Sale | $199.24 | -341 | 52,868 | -1% | -$67,941 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale | $199.24 | -1,774 | 42,116 | -4% | -$353,449 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $199.24 | -5,569 | 286,307 | -2% | -$1,109,554 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $199.24 | -4,967 | 149,680 | -3% | -$989,613 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $199.24 | -13,988 | 970,250 | -1% | -$2,786,938 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | SVP, GC | S - Sale | $199.24 | -3,366 | 52,541 | -6% | -$670,631 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $199.24 | -4,053 | 119,216 | -3% | -$807,513 | ||||||
| M | 2026-09-17 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $97.49 | -64,000 | 39,707,320 | 0% | -$6,239,071 | |||||
2026-09-17 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.21 | +24,000 | 126,822 | +23% | +$4,992 | ||||||
2026-09-15 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $27.00 | -1,195 | 395,794 | 0% | -$32,265 | ||||||
2026-09-16 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $100.00 | +5,000 | 1,069,046 | 0% | +$500,000 | ||||||
2026-09-16 | HALO | Halozyme Therapeutics, Inc. | Posard Matthew L. | Dir | S - Sale | $107.74 | -18,996 | 58,839 | -24% | -$2,046,581 | ||||||
| D | 2026-09-15 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $72.98 | -1,000 | 0 | -100% | -$72,980 | |||||
| D | 2026-09-15 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale+OE | $78.38 | -12,500 | 94,487 | -12% | -$979,744 | |||||
2026-09-16 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.21 | +11,000 | 102,822 | +12% | +$2,310 | ||||||
| M | 2026-09-14 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.57 | +123,918 | 3,272,141 | +4% | +$1,062,506 | |||||
2026-09-14 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $13.90 | -58,333 | 767,486 | -7% | -$811,004 | ||||||
| DM | 2026-09-14 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $145.10 | -80,575 | 1,718,078 | -4% | -$11,691,420 | |||||
| M | 2026-09-15 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $96.37 | -49,000 | 39,771,320 | 0% | -$4,721,976 | |||||
2026-09-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $145.29 | -3,000 | 164,096 | -2% | -$435,870 | ||||||
2026-09-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale | $144.22 | -3,000 | 116,684 | -3% | -$432,646 | ||||||
2026-09-15 | DNA | Ginkgo Bioworks Holdings, Inc. | Henry Christian O | Dir | S - Sale | $7.08 | -5,000 | 19,310 | -21% | -$35,405 | ||||||
| D | 2026-09-15 | FENC | Fennec Pharmaceuticals Inc. | Brughera Marco Maria | Dir | S - Sale+OE | $10.29 | -15,545 | 0 | -100% | -$159,958 | |||||
2026-09-15 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.22 | +22,000 | 91,822 | +32% | +$4,862 | ||||||
2026-09-14 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $1.93 | -2,587 | 601,971 | 0% | -$4,993 | ||||||
2026-09-14 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.93 | -1,658 | 502,907 | 0% | -$3,200 | ||||||
| D | 2026-09-11 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $202.36 | -92,531 | 291,876 | -24% | -$18,724,767 | |||||
| M | 2026-09-11 | INBX | Inhibrx Biosciences, Inc. | Manhard Kimberly | Dir | S - Sale | $109.03 | -1,500 | 7,500 | -17% | -$163,543 | |||||
2026-09-14 | NBIX | Neurocrine Biosciences Inc | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $157.45 | -826 | 8,722 | -9% | -$130,051 | ||||||
2026-09-14 | NBIX | Neurocrine Biosciences Inc | Abernethy Matt | CFO | S - Sale | $157.20 | -2,311 | 42,808 | -5% | -$363,285 | ||||||
2026-09-14 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.22 | +5,900 | 69,822 | +9% | +$1,292 | ||||||
2026-09-14 | HUMA | Humacyte, Inc. | Jones Keith Anthony | Dir | P - Purchase | $0.56 | +10,000 | 50,000 | +25% | +$5,620 | ||||||
| D | 2026-09-10 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $204.16 | -15,448 | 43,890 | -26% | -$3,153,807 | |||||
| D | 2026-09-10 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $134.49 | -34,836 | 59,375 | -37% | -$4,685,094 | |||||
2026-09-09 | OCGN | Ocugen, Inc. | Musunuri Shankar | CEO | S - Sale | $1.12 | -525,991 | 5,575,232 | -9% | -$589,110 | ||||||
| DM | 2026-09-09 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $107.28 | -60,000 | 767,780 | -7% | -$6,436,711 | |||||
2026-09-09 | MGX | Metagenomi Therapeutics, Inc. | Reid Laurence | Dir | P - Purchase | $1.17 | +20,000 | 20,000 | New | +$23,401 | ||||||
| DM | 2026-09-10 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO | S - Sale+OE | $11.28 | -280,245 | 113,321 | -71% | -$3,160,783 | |||||
2026-09-10 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $96.31 | -20,500 | 39,906,320 | 0% | -$1,974,287 | ||||||
| D | 2026-09-09 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $154.61 | -2,154 | 64,408 | -3% | -$333,030 | |||||
| M | 2026-09-08 | INBX | Inhibrx Biosciences, Inc. | Manhard Kimberly | Dir | S - Sale | $115.47 | -1,000 | 9,000 | -10% | -$115,468 | |||||
2026-09-08 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | CEO, Pres | S - Sale | $3.52 | -22,408 | 2,072,890 | -1% | -$78,822 | ||||||
2026-09-08 | RVMD | Revolution Medicines, Inc. | Kim Lorence H. | Dir | S - Sale | $209.82 | -17,090 | 1,191 | -93% | -$3,585,837 | ||||||
2026-09-08 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $122.62 | -412 | 73,651 | -1% | -$50,521 | ||||||
2026-09-08 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $122.62 | -907 | 117,014 | -1% | -$111,220 | ||||||
| D | 2026-09-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $122.62 | -2,302 | 768,427 | 0% | -$282,280 | |||||
2026-09-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $122.62 | -238 | 44,399 | -1% | -$29,185 | ||||||
2026-09-08 | MGX | Metagenomi Therapeutics, Inc. | Wein Matthew | See Remarks | S - Sale | $1.16 | -358 | 126,133 | 0% | -$415 | ||||||
2026-09-08 | MGX | Metagenomi Therapeutics, Inc. | Irish Jian | See Remarks | S - Sale | $1.16 | -2,140 | 960,820 | 0% | -$2,479 | ||||||
2026-09-08 | MGX | Metagenomi Therapeutics, Inc. | Wapnick Pamela | CFO | S - Sale | $1.16 | -1,911 | 206,580 | -1% | -$2,214 | ||||||
| D | 2026-09-08 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $21.57 | -8,000 | 158,844 | -5% | -$172,560 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |